Vivimed Labs Limited
Vivimed Labs Ltd is primarily engaged in the business of APIs, CDMO, Finished Dosage Formulation, Specialty Chemicals and retail branded formulation manufacturing.
What Vivimed files
- Others28
- Important21
- Updates11
- Board Meeting6
- Results3
Vivimed Labs has published financial results for the quarter and year ended March 31, 2026. These results were approved by the Board of Directors. Full details are available on stock exchange and company websites.
Vivi Med Labs' Registrar reported *zero* shareholder requests received or processed for re-lodgement of physical shares. All related metrics, including approvals and rejections, were NIL. No operational activity.
Vivimed Labs' equity share trading suspension is revoked. This significant development reinstates liquidity and enables crucial price discovery for shareholders, following the company's diligent compliance with regulatory requirements. Positive for investors.
Vivimed Labs has called an EGM to approve a preferential issue of up to 4 Cr equity shares at ₹14.50 each, raising ₹58 Cr. The company will also seek to increase its authorized share capital from ₹35 Cr to ₹75 Cr.
Company announced an EGM to approve increasing share capital to ₹25 Cr. It proposes a Rights Issue, offering new shares at a minimum of ₹50 each (face value ₹10). This aims to raise capital.